Asunaprevir: all 29 studies that test it
Page 1 of 1. Open to participants first (0), then studies with results posted, then the rest; newest registration first within each.
- Short Duration Combination Therapy With Daclatasvir, Asunaprevir, BMS-791325 and Sofosbuvir in Subjects Infected With Chronic Hepatitis-C (FOURward Study)CompletedNCT02175966Phase 2Results posted
- A Phase 3 Study of a Daclatasvir/Asunaprevir/BMS-791325 Fixed Dose Combination (FDC) in Subjects With Chronic Hepatitis C Genotype 1CompletedNCT02170727Phase 3Results posted
- Safety, Tolerability, and Efficacy of Asunaprevir and Daclatasvir in Subjects Coinfected With HIV-HCVCompletedNCT02124044Phase 2Results posted
- Phase III China GT 1b Interferon (IFN) Intolerant Prev Exclude DualCompletedNCT01995266Phase 3Results posted
- Study of pegInterferon Alfa-2a, Ribavirin, and Daclatasvir (BMS-790052) With or Without BMS-650032 for Participants in Some Hepatitis C Virus TrialsCompletedNCT01428063Phase 2Results posted
- Daclatasvir, Asunaprevir Plus Ribavirin for HCV Genotype 1b Without NS5A RAVCompletedNCT03004625Phase 3
- The Safety and Efficacy of Daclatasvir and Asunaprevir With Chronic HCV Genotype 1b Infection and Chronic Renal FailureCompletedNCT02580474Phase 4
- A Phase 3 Evaluation of Daclatasvir and Asunaprevir in Treatment-naive Subjects With Chronic Hepatitis C Genotype 1b InfectionCompletedNCT02496078Phase 3
- A Bioequivalence Study of Daclatasvir Tablets and Bioavailability Studies of Daclatasvir and AsunaprevirCompletedNCT02323594Phase 1
- Effect of ASV and DCV Therapy on the Quality of Immune Status in Chronic HCV PatientsCompletedNCT02282709Phase 3
- To Assess the Effect of Renal Impairment on the Blood Levels of Daclatasvir (DCV), Asunaprevir (ASV) and BMS-791325 After Multiple Doses of a Fixed Dose Combination TabletCompletedNCT02108639Phase 1
- Therapy With Asunaprevir, Daclatasvir, Ribavirin and Pegylated Interferon Alpha-2a in HCV Genotype 4-infected Patients Who Have Failed to a Previous Therapy With Peg-Interferon/Ribavirin (ANRS HC32 QUATTRO)CompletedNCT02107365Phase 2
- Drug Interaction Between Daclatasvir/Asunaprevir/BMS-791325 and RosuvastatinCompletedNCT02104843Phase 1
- Rapid Hepatitis C Elimination Trial- A Pilot Study of Daclatasvir/Asunaprevir/BMS-791325 With or Without Ribavirin To Treat Hepatitis C VirusCompletedNCT02098616Not applicable
- Food Effect of a Fixed Dose Combination of Daclatasvir, Asunaprevir and BMS-791325CompletedNCT02095860Phase 1
- Drug Interaction & Methadone & BuprenorphineCompletedNCT02045693Phase 1
- UNITY 1: A Study of an Investigational Treatment Regimen of Daclatasvir (DCV) + Asunaprevir (ASV) + BMS-791325 in a Fixed Dose Combination (the DCV 3DAA (Direct Acting Antiviral) Regimen) for 12 Weeks for the Treatment of Chronic Hepatitis C Virus (HCV) Genotype 1 Infection in Non-cirrhotic SubjectsCompletedNCT01979939Phase 3
- Study of the Pharmacokinetics and Safety of Asunaprevir in Patients With Kidney DiseaseCompletedNCT01886599Phase 1
- Pilot Study to Assess the Efficacy of and Tolerance to a QUadruple Therapy to Treat HIV-HCV Coinfected Patients Previously Null RespondersCompletedNCT01725542Phase 2
- A Phase 3, Comparative Study of Asunaprevir and Daclatasvir Combination Therapy Versus Telaprevir Therapy in Japanese HCV SubjectsCompletedNCT01718145Phase 3
- Phase III Hallmark QUAD: ASV+DCV+Peg+Rib (Nulls/Partials)CompletedNCT01573351Phase 3
- A Phase 3 Study in Combination With BMS-790052 and BMS-650032 in Japanese Hepatitis C Virus (HCV) PatientsCompletedNCT01497834Phase 3
- Safety Study of Pegylated Interferon Lambda Plus Single or 2 Direct Antiviral Agents With RibavirinCompletedNCT01309932Phase 2
- Drug Interaction Oral Contraceptive Pill (OCP)CompletedNCT01063023Phase 1
- An Anti-viral Combination Study With Japanese Hepatitis C Infection (HCV) SubjectCompletedNCT01051414Phase 2
- Study of BMS-650032 With Peginterferon Alfa-2a Plus RibavirinCompletedNCT01030432Phase 2
- Hepatic Impaired Subjects Compared to Healthy Subjects Receiving Multi-dose BMS-650032CompletedNCT01019070Phase 1
- Drug-Drug Interaction Study in Healthy SubjectsCompletedNCT00904059Phase 1
- A Multiple Ascending Dose Study of BMS-650032 in HCV Infected SubjectsCompletedNCT00722358Phase 2